Penina Ponger
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Penina Ponger has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
Achinoam Faust‐Socher
Neurological institute Tel‐Aviv Sourasky Medical Center Tel Aviv Israel
1 shared publicationAdi Mory
Genetics Institute and Genomics Center Tel Aviv Sourasky Medical Center Tel Aviv Israel
1 shared publicationAlina Kurolap
Faculty of Medical & Health Sciences, Tel Aviv University Tel Aviv Israel
1 shared publication- Anuprita R. Nair
Department of Biostatistics, University of Iowa
1 shared publication Avner Thaler
Neurological institute Tel‐Aviv Sourasky Medical Center Tel Aviv Israel
1 shared publicationChelsea Caspell-Garcia
Department of Biostatistics, College of Public Health, University of Iowa, Iowa City, IA, USA
1 shared publication
Latest Publications
- Open Access
- 20 July 2026
- Published by Springer Nature in Communications Medicine
- Vol. 6 (1)
Integrating remote testing and machine learning to identify markers of cerebellar ataxia at home
- 20 July 2026
- Published by Springer Nature in Communications Medicine
- Vol. 6 (1)
Open AccessIntegrating remote testing and machine learning to identify markers of cerebellar ataxia at home
- Open Access
SAA positivity rate amongst dual LRRK2-GBA1, GBA1 and LRRK2 carriers with Parkinson’s disease
We investigated whether people with Parkinson’s disease who are dual GBA1+LRRK2 carriers have a milder, LRRK2-like phenotype as previously reported. This was accomplished by comparing clinical features and alpha-synuclein seed amplification assay (SAA) positivity rates between dual GBA1+LRRK2-PD(n=13), GBA1-PD(n=169) and LRRK2-PD(n=175) carriers in a cross-sectional retrospective study of Parkinson’s Progression Markers Initiative (PPMI) data. Our results show that GBA1+LRRK2-PD SAA positivity rate(83%) is closer to GBA1-PD rate(87%) rather than LRRK2-PD rate(62%,p-value>0.05). GBA1+LRRK2-PD have both non-motor and motor phenotypic similarity to GBA1-PD,(p-value>0.05). This small PPMI cohort indicates that dual GBA1+LRRK2-PD carriers’ SAA positivity and phenotype are aligned with GBA1-PD.
Open AccessSAA positivity rate amongst dual LRRK2-GBA1, GBA1 and LRRK2 carriers with Parkinson’s disease
We investigated whether people with Parkinson’s disease who are dual GBA1+LRRK2 carriers have a milder, LRRK2-like phenotype as previously reported. This was accomplished by comparing clinical features and alpha-synuclein seed amplification assay (SAA) positivity rates between dual GBA1+LRRK2-PD(n=13), GBA1-PD(n=169) and LRRK2-PD(n=175) carriers in a cross-sectional retrospective study of Parkinson’s Progression Markers Initiative (PPMI) data. Our results show that GBA1+LRRK2-PD SAA positivity rate(83%) is closer to GBA1-PD rate(87%) rather than LRRK2-PD rate(62%,p-value>0.05). GBA1+LRRK2-PD have both non-motor and motor phenotypic similarity to GBA1-PD,(p-value>0.05). This small PPMI cohort indicates that dual GBA1+LRRK2-PD carriers’ SAA positivity and phenotype are aligned with GBA1-PD.
- Open Access
- 5 June 2025
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 12 (11) , 1811-1820
High Genetic Diagnostic Yield for Patients with Rare Movement Disorders at a Single‐Center Neurogenetics Clinic
Background: As advanced molecular testing is incorporated into routine clinical practice, accessibility and yield remain limited. Objectives: We propose a simplified and effective workup strategy to maximize diagnostic yield based on presented diagnostic yield of rare movement disorders at a tertiary Neurogenetics Clinic. Methods: Retrospective analysis (2019–2023) of 190 patients aged 2–87 years, diagnosed with cerebellar ataxia (CA, n = 91), hereditary spastic paraparesis (HSP, n = 51), or dystonia and paroxysmal dyskinesia movement disorders (DPD, n = 48). Workup included next‐generation sequencing (NGS) and repeat expansion testing. Undiagnosed cases underwent exome or genome sequencing (ES/GS). Results: Among 190 patients, 38 had a prior genetic diagnosis, and 106 were undiagnosed patients who pursued workup; 43 of 106 (41%) cases were genetically diagnosed: 25 of 43(58%) by NGS, 13 of 43 (30%) by repeat expansion analysis, and 5 of 43(12%) by sequencing for founder mutation or target gene. Diagnostic rate in the newly diagnosed CA subgroup reached 52%, 30% in HSP and 32% in DPD. In the overall cohort, the diagnostic yield of NGS panels was 31% and 33% for ES. Diagnostic yield was significantly higher ( P ‐value<0.05) among patients with early‐onset disease or isolated phenotypes. Conclusions: We report a high diagnostic yield (41%) compared to reported literature (20%–30%), especially in patients with early‐onset disease. ES, compared to panel testing, was of greater contribution to diagnosis of complex phenotypes. Our findings argue for early referral to genetic workup, suggesting that tailored workup based on phenotype complexity and age of onset can reduce auxiliary testing. Further cost–benefit analysis is required to lower expenses and ensure timely diagnosis.
- 5 June 2025
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 12 (11) , 1811-1820
Open AccessHigh Genetic Diagnostic Yield for Patients with Rare Movement Disorders at a Single‐Center Neurogenetics Clinic
Background: As advanced molecular testing is incorporated into routine clinical practice, accessibility and yield remain limited. Objectives: We propose a simplified and effective workup strategy to maximize diagnostic yield based on presented diagnostic yield of rare movement disorders at a tertiary Neurogenetics Clinic. Methods: Retrospective analysis (2019–2023) of 190 patients aged 2–87 years, diagnosed with cerebellar ataxia (CA, n = 91), hereditary spastic paraparesis (HSP, n = 51), or dystonia and paroxysmal dyskinesia movement disorders (DPD, n = 48). Workup included next‐generation sequencing (NGS) and repeat expansion testing. Undiagnosed cases underwent exome or genome sequencing (ES/GS). Results: Among 190 patients, 38 had a prior genetic diagnosis, and 106 were undiagnosed patients who pursued workup; 43 of 106 (41%) cases were genetically diagnosed: 25 of 43(58%) by NGS, 13 of 43 (30%) by repeat expansion analysis, and 5 of 43(12%) by sequencing for founder mutation or target gene. Diagnostic rate in the newly diagnosed CA subgroup reached 52%, 30% in HSP and 32% in DPD. In the overall cohort, the diagnostic yield of NGS panels was 31% and 33% for ES. Diagnostic yield was significantly higher ( P ‐value<0.05) among patients with early‐onset disease or isolated phenotypes. Conclusions: We report a high diagnostic yield (41%) compared to reported literature (20%–30%), especially in patients with early‐onset disease. ES, compared to panel testing, was of greater contribution to diagnosis of complex phenotypes. Our findings argue for early referral to genetic workup, suggesting that tailored workup based on phenotype complexity and age of onset can reduce auxiliary testing. Further cost–benefit analysis is required to lower expenses and ensure timely diagnosis.